Search results for "chemotherapy. radiotherapy"

showing 3 items of 3 documents

Vinblastine, bleomycin, and methotrexate chemotherapy plus irradiation for patients with early-stage, favorable Hodgkin lymphoma

2003

BACKGROUND. The acknowledged effectiveness of vinblastine, bleomycin, and methotrexate (VBM) chemotherapy in patients with early-stage Hodgkin lymphoma has been associated with conflicting toxicity reports. METHODS. One hundred forty-three patients were evaluated clinically and had favorable Stage IA or IIA Hodgkin lymphoma. Ninety-three patients were treated with the standard VBM schedule combined with extended-field radiotherapy (EFRT), leaving the choice of the therapeutic sequence free. Fifty subsequent patients were treated with a slightly modified VBM schedule (VbMp) combined with RT limited to involved fields (IF-RT) and delivered only after the end of chemotherapy. In the VbMp sched…

AdultMaleCancer Researchmedicine.medical_specialtyAdolescentPulmonary toxicitymedicine.drug_classmedicine.medical_treatmentchemotherapyBleomycinGastroenterologyAntimetaboliteBleomycinchemistry.chemical_compoundHodgkinPrednisoneInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansLungradiotherapyAgedChemotherapybusiness.industryHodgkin; chemotherapy; radiotherapy; toxicitytoxicityMiddle AgedCombined Modality TherapyHodgkin DiseaseSurgeryVinblastineRegimenMethotrexateTreatment OutcomeOncologychemistryVincristineFemaleMethotrexateNeoplasm Recurrence Localbusinessmedicine.drugCancer
researchProduct

Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treat…

2020

Background Cancer patients are thought to have an increased risk of developing severe Coronavirus Disease 2019 (COVID-19) infection and of dying from the disease. In this work, predictive factors for COVID-19 severity and mortality in cancer patients were investigated. Patients and Methods In this large nationwide retro-prospective cohort study, we collected data on patients with solid tumours and COVID-19 diagnosed between March 1 and June 11, 2020. The primary endpoint was all-cause mortality and COVID-19 severity, defined as admission to an intensive care unit (ICU) and/or mechanical ventilation and/or death, was one of the secondary endpoints. Results From April 4 to June 11, 2020, 1289…

Male0301 basic medicineCancer Researchmedicine.medical_treatmentDiseaselaw.inventionCohort Studies0302 clinical medicineMechanical ventilationRisk FactorslawNeoplasmsMedicineProspective StudiesProspective cohort studyOriginal ResearchCancerIntensive care unit3. Good healthDeathOncology030220 oncology & carcinogenesisFemaleFranceImmunotherapyCohort studymedicine.medical_specialtychemotherapy. radiotherapyAntineoplastic Agents[SDV.CAN]Life Sciences [q-bio]/Cancer03 medical and health sciencesInternal medicineHumansChemotherapyIntensive care unitMortalityPandemicsAgedRetrospective StudiesChemotherapyRadiotherapySARS-CoV-2business.industryCancerCOVID-19Retrospective cohort studyOdds ratiomedicine.diseaseAged; Antineoplastic Agents/adverse effects; Antineoplastic Agents/therapeutic use; COVID-19/mortality; Cohort Studies; Female; France/epidemiology; Humans; Male; Neoplasms/mortality; Neoplasms/therapy; Neoplasms/virology; Pandemics; Prospective Studies; Retrospective Studies; Risk Factors; SARS-CoV-2/isolation & purification; COVID-19; Cancer; Chemotherapy; Death; Immunotherapy; Intensive care unit; Mechanical ventilation; Mortality; Radiotherapy030104 developmental biologybusiness
researchProduct

Anticancer therapy-induced vascular toxicity: VEGF inhibition and beyond

2017

Cardiotoxicity induced by chemotherapeutic agents and radiotherapy is a growing problem. In recent years, an increasing number of new drugs with targeted action have been designed. These molecules, such as monoclonal antibodies and tyrosine kinase inhibitors, can cause different type of toxicities compared to traditional chemotherapy. However, they can also cause cardiac complications such as heart failure, arterial hypertension, QT interval prolongation and arrhythmias. Currently, a field of intense research is the vascular toxicity induced by new biologic drugs, particularly those which inhibit vascular endothelial growth factor (VEGF) and its receptor (VEGF-R) and other tyrosine kinases.…

Vascular Endothelial Growth Factor APathologymedicine.medical_specialtyHeart Diseasesmedicine.medical_treatmentVascular toxicity VEGF cardiotoxicity new target therapy chemotherapy radiotherapy cardio-oncologyAntineoplastic Agents030204 cardiovascular system & hematologyQT intervalCardiooncology03 medical and health scienceschemistry.chemical_compoundCardio-oncology; Cardiotoxicity; Chemotherapy; New target therapy; Radiotherapy; Vascular toxicity; VEGF; Medicine (all); Cardiology and Cardiovascular Medicine0302 clinical medicineVascularReceptorsmedicineAnimalsHumansChemotherapyEndotheliumNew target therapyChemotherapyCardiotoxicityRadiotherapybusiness.industryVascular Endothelial Growth FactorMedicine (all)Cardiooncology; Vascular toxicity; New target therapyCardio-oncology; Cardiotoxicity; Chemotherapy; New target therapy; Radiotherapy; Vascular toxicity; VEGF; Animals; Antineoplastic Agents; Cardiotoxicity; Endothelium Vascular; Heart Diseases; Humans; Reactive Oxygen Species; Receptors Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor Amedicine.diseaseVEGFCardiotoxicityVascular endothelial growth factorRadiation therapyCardio-oncologyVascular endothelial growth factor AReceptors Vascular Endothelial Growth Factorchemistry030220 oncology & carcinogenesisHeart failureCancer researchEndothelium VascularVascular toxicityReactive Oxygen SpeciesCardiology and Cardiovascular MedicinebusinessTyrosine kinaseInternational Journal of Cardiology
researchProduct